(Boursier.com) — The Board of Directors GenSight Biologics took note of the resignation of Bernard Gilly from his mandate as director.
The Board of Directors also announces its decision, after consultation with the Nominations Committee, to co-opt Laurence Rodriguez as director for the remaining term of office of Bernard Gilly, i.e. until the end of the general meeting. ordinary which will be called upon to rule in 2024 on the accounts for the financial year ending December 31, 2023.
The co-optation of Laurence Rodriguez will be subject to ratification at the next general meeting.
The appointment of Laurence Rodriguez as Chief Executive Officer of the Company took effect on December 21, 2023.
The board of directors of GenSight Biologics would like to thank Bernard Gilly, co-founder of the company in 2012 alongside Professor José-Alain Sahel, “for his many years of dedication within the company, and his essential contribution to making of Lumevoq a therapy capable of transforming patients’ lives”.
The Board of Directors of GenSight Biologics is made up of 8 members, including 5 independent directors and one observer.
©2024 Boursier.com